Amy S. Rosenberg, MD

Articles by Amy S. Rosenberg, MD

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 3: Effects of Manufacturing Changes in Immunogenicity and the Utility of Animal Immunogenicity Studies

ByAmy S. Rosenberg, MD,Alexandra Worobec, M.D.

January 1st 2005

Manufacturing changes - such as changes in formulation or source material - can impact a product’s immunogenicity.

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 1: Considering Consequences of the Immune Response to a Protein

ByAmy S. Rosenberg, MD,Alexandra Worobec, M.D.

November 1st 2004

Neutralization of therapeutic protein products does not produce an obvious clinical deficiency syndrome for all therapeutic protein products with endogenous counterparts, because many endogenous proteins are biologically redundant.

Latest Updated Articles

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 3: Effects of Manufacturing Changes in Immunogenicity and the Utility of Animal Immunogenicity Studies
Published: January 1st 2005 | Updated:
A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 1: Considering Consequences of the Immune Response to a Protein
Published: November 1st 2004 | Updated:

Amy S. Rosenberg, MD

Articles by Amy S. Rosenberg, MD

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 3: Effects of Manufacturing Changes in Immunogenicity and the Utility of Animal Immunogenicity Studies

A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 1: Considering Consequences of the Immune Response to a Protein

Latest Updated Articles

Trending on BioPharm International

Analytics, Automation, and Quality Driving the Next Era of Drug Development

Therapeutic Nucleic Acids: Advanced Solutions for Downstream Processing & Analysis

Rentschler’s Time Capsule and How it Symbolizes European Biotech Progress